Financial Results Approval

The Board considered and approved the unaudited financial results for the quarter ended June 30, 2026 (Q1 FY27) on both standalone and consolidated basis, along with the Limited Review Report.

Standalone Financial Results (₹ in million)

  • Revenue from operations: ₹3,284.85 (Q1 FY27) vs ₹2,779.87 (Q1 FY26) vs ₹3,124.23 (Q4 FY26)
  • Other income: ₹106.43 (Q1 FY27) vs ₹128.36 (Q1 FY26) vs ₹89.46 (Q4 FY26)
  • Total income: ₹3,391.28 (Q1 FY27) vs ₹2,908.23 (Q1 FY26) vs ₹3,213.69 (Q4 FY26)
  • Employee benefit expense: ₹569.54 (Q1 FY27) vs ₹473.89 (Q1 FY26) vs ₹517.39 (Q4 FY26)
  • Professional fees: ₹804.06 (Q1 FY27) vs ₹644.08 (Q1 FY26) vs ₹725.94 (Q4 FY26)
  • Finance costs: ₹81.16 (Q1 FY27) vs ₹30.01 (Q1 FY26) vs ₹42.23 (Q4 FY26)
  • Profit before tax: ₹501.13 (Q1 FY27) vs ₹607.50 (Q1 FY26) vs ₹655.44 (Q4 FY26)
  • Tax expense: ₹129.24 (Q1 FY27) vs ₹174.56 (Q1 FY26) vs ₹163.40 (Q4 FY26)
  • Net profit: ₹371.89 (Q1 FY27) vs ₹432.94 (Q1 FY26) vs ₹492.04 (Q4 FY26)
  • EPS (Basic): ₹5.67 (Q1 FY27) vs ₹6.60 (Q1 FY26) vs ₹7.51 (Q4 FY26)
  • Paid-up equity share capital: ₹655.66 million (face value ₹10 per share)

Consolidated Financial Results (₹ in million)

  • Revenue from operations: ₹4,109.83 (Q1 FY27) vs ₹3,529.53 (Q1 FY26) vs ₹3,878.38 (Q4 FY26)
  • Other income: ₹105.86 (Q1 FY27) vs ₹128.17 (Q1 FY26) vs ₹91.49 (Q4 FY26)
  • Total income: ₹4,215.69 (Q1 FY27) vs ₹3,657.70 (Q1 FY26) vs ₹3,969.87 (Q4 FY26)
  • Profit before tax: ₹505.53 (Q1 FY27) vs ₹617.48 (Q1 FY26) vs ₹675.56 (Q4 FY26)
  • Tax expense: ₹130.41 (Q1 FY27) vs ₹178.03 (Q1 FY26) vs ₹172.89 (Q4 FY26)
  • Net profit: ₹375.12 (Q1 FY27) vs ₹439.45 (Q1 FY26) vs ₹502.67 (Q4 FY26)
  • Profit attributable to owners: ₹374.86 (Q1 FY27) vs ₹438.86 (Q1 FY26) vs ₹506.15 (Q4 FY26)
  • EPS (Basic): ₹5.72 (Q1 FY27) vs ₹6.69 (Q1 FY26) vs ₹7.66 (Q4 FY26)

Management Appointment

The Board approved the appointment of Mr. Harshad Purani as Chief Financial Officer and Key Managerial Personnel effective July 31, 2026. Mr. Purani has been with the company since September 2007 and currently serves as President - Administration and Head of Corporate Social Responsibility. He holds a bachelor's degree in commerce and an international executive MBA.

Subsidiary Acquisition

Jupiter Hospital Pharmacy Private Limited (JHPPL), a subsidiary, acquired 100% of the equity share capital of Sulcus Private Limited for a consideration of ₹3.78 crore. Consequently, Sulcus has become a wholly owned subsidiary of JHPPL and a step-down subsidiary of Jupiter Life Line Hospitals Limited.

Acquisition Details:

  • Sulcus Private Limited was incorporated on August 23, 2012
  • Engaged in setting up an IV fluids, infusions and pharmaceutical manufacturing facility near Ujjain, Madhya Pradesh
  • Acquisition based on independent valuation and arm's length basis
  • Previous shareholders: Dr. Ankit Thakker and Ms. Kirtika Thakker
  • Government approval obtained from DMIC Vikram Udyogpuri Limited (Ref: DMIC/VUL/LM/2026/121 dated June 30, 2026)
  • Share Purchase Agreement signed on July 31, 2026

Strategic Rationale: JHPPL operates retail pharmacy stores in Jupiter Hospitals. The acquisition aims to reduce costs and improve margins by establishing pharmaceutical manufacturing capabilities. Sulcus has an industrial land near Ujjain for setting up the manufacturing facility.

Future Investment: Estimated investment of ₹35-40 crore required over 1-2 years for one line of blow-fill-seal IV fluid filling machine.

Other Matters

The financial results include the company's share of net loss after tax of ₹3.24 million from a partnership firm for the quarter ended June 30, 2025 (standalone) and ₹3.41 million for June 30, 2026 (consolidated), which management considers immaterial.

The proposed merger of Medulla Healthcare Private Limited (wholly-owned subsidiary) with Jupiter Life Line Hospitals Limited with effect from April 1, 2025 is pending final sanction from the National Company Law Tribunal, Mumbai. The effect of the proposed scheme is not reflected in the current financial statements as it is not material.

During previous year ended March 31, 2026, the company recognized ₹43.89 million (standalone) and ₹48.87 million (consolidated) towards increase in gratuity liability arising from enactment of new Labour Codes under "Exceptional Items."

The Board meeting commenced at 3:00 PM and concluded at 3:45 PM on July 31, 2026.